"versionIdentifier","instanceType","uuid:ID","id","rationale"
"2","StudyVersion","51ac094f-0bff-41f9-8ef3-2011c3554150","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
